γδ T cells as unconventional targets of checkpoint blockade

Hans R. Widlund; Lydia Lynch

doi:10.1038/s43018-024-00735-y

γδ T cells as unconventional targets of checkpoint blockade

Hans R. Widlund, Lydia Lynch

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Identifying which patients will benefit most from immune checkpoint blockade (ICB) is an important clinical challenge. A study now finds that Vδ1⁺ γδ T cells are associated with better response to ICB in melanoma tumors with a lower neoantigen load and shows that some effector functions of PD-1⁺ Vδ1⁺ T cells are repressed after engagement of PD-1 by PD-L1.

Original language	English (US)
Pages (from-to)	373-374
Number of pages	2
Journal	Nature Cancer
Volume	5
Issue number	3
DOIs	https://doi.org/10.1038/s43018-024-00735-y
State	Published - Mar 2024
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1038/s43018-024-00735-y

Cite this

@article{1876ca3ddcfe493a8f41432456ae15c5,

title = "γδ T cells as unconventional targets of checkpoint blockade",

abstract = "Identifying which patients will benefit most from immune checkpoint blockade (ICB) is an important clinical challenge. A study now finds that Vδ1+ γδ T cells are associated with better response to ICB in melanoma tumors with a lower neoantigen load and shows that some effector functions of PD-1+ Vδ1+ T cells are repressed after engagement of PD-1 by PD-L1.",

author = "Widlund, \{Hans R.\} and Lydia Lynch",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc 2024.",

year = "2024",

month = mar,

doi = "10.1038/s43018-024-00735-y",

language = "English (US)",

volume = "5",

pages = "373--374",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - γδ T cells as unconventional targets of checkpoint blockade

AU - Widlund, Hans R.

AU - Lynch, Lydia

N1 - Publisher Copyright: © Springer Nature America, Inc 2024.

PY - 2024/3

Y1 - 2024/3

N2 - Identifying which patients will benefit most from immune checkpoint blockade (ICB) is an important clinical challenge. A study now finds that Vδ1+ γδ T cells are associated with better response to ICB in melanoma tumors with a lower neoantigen load and shows that some effector functions of PD-1+ Vδ1+ T cells are repressed after engagement of PD-1 by PD-L1.

AB - Identifying which patients will benefit most from immune checkpoint blockade (ICB) is an important clinical challenge. A study now finds that Vδ1+ γδ T cells are associated with better response to ICB in melanoma tumors with a lower neoantigen load and shows that some effector functions of PD-1+ Vδ1+ T cells are repressed after engagement of PD-1 by PD-L1.

UR - https://www.scopus.com/pages/publications/85189146024

UR - https://www.scopus.com/inward/citedby.url?scp=85189146024&partnerID=8YFLogxK

U2 - 10.1038/s43018-024-00735-y

DO - 10.1038/s43018-024-00735-y

M3 - Comment/debate

C2 - 38538909

AN - SCOPUS:85189146024

SN - 2662-1347

VL - 5

SP - 373

EP - 374

JO - Nature Cancer

JF - Nature Cancer

IS - 3

ER -

γδ T cells as unconventional targets of checkpoint blockade

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this